US MFN and Its Implications for Pharmaceutical Access
A multinational white paper exploring how emerging US Most Favored Nation pricing policies could reshape global pricing strategy, launch sequencing, evidence generation, and pharmaceutical access. Developed with expert input across key MFN reference markets.
Why this white paper matters
US MFN policy is no longer just a pricing headline. It is becoming a strategic planning issue with implications far beyond the US market. This white paper examines how proposed Medicaid and Medicare MFN models could change manufacturer behavior, alter launch priorities, compress global pricing flexibility, and increase the importance of confidential ex-US net prices.
Built by a multinational expert network, the paper combines country-level market access knowledge with a global strategic lens to help pharmaceutical companies navigate a rapidly evolving policy environment.
What readers will learn
- A clear view of the evolving MFN landscape
The paper explains how current MFN proposals differ across Medicaid and Medicare, including the voluntary GENEROUS Medicaid framework and the proposed GLOBE and GUARD Medicare models. It also clarifies which countries sit inside the reference sets most relevant to manufacturers today.
- Cross-market implications for pricing and access
The analysis shows why pricing decisions outside the US can no longer be managed in isolation, arguing that the US effectively becomes the new anchor market in global pricing strategy under MFN-style dynamics.
- Practical strategic implications for manufacturers
Readers will see how MFN may drive delayed or more selective ex-US launches, narrowing of global pricing corridors, greater reliance on confidential ex-US net prices, tighter lifecycle price discipline, and alternative channel strategies such as private-market access pathways.
- Actionable recommendations
The paper offers practical guidance on launch sequencing, evidence generation, centralized global pricing governance, alternative access channels, and long-term value defense in markets with post-launch price renegotiation risk.
Key themes explored in the white paper
The US becomes more central to global pricing strategy
Launch sequencing may need to change
Evidence strategy becomes a market access lever
Risk management will rely more heavily on contracting sophistication
The report argues that ex-US price decisions may directly affect US revenue exposure, making globally coordinated pricing and access strategy essential.
Manufacturers may prioritize non-MFN countries differently, delay launches in higher-risk MFN markets, and update IRP tools to reflect second-order reference risks.
The report highlights targeted populations, pre-specified subgroup analyses, differentiated indication launches, and variant-specific evidence packages as tools to preserve optionality across markets.
Innovative agreements, pricing non-transparency, and alternative channels may become increasingly important where public pricing creates unacceptable MFN or IRP exposure.
Developed by a multinational expert network
This report brings together expertise from the US, UK, France, Germany, Italy, Canada, Japan, the Nordics, and Switzerland to provide both country-level detail and a globally coordinated strategic view.
